银诺医药-B(02591.HK)：已在澳大利亚完成依苏帕格鲁肽α用于治疗肥胖和超重的II期临床试验的首例患者给药

Core Viewpoint - Company plans to initiate a Phase II clinical trial for its core product, Isuparaglutide α, targeting obesity and overweight in Australia in the second half of 2025 [1] Group 1 - The company has completed the first patient dosing for the Phase II clinical trial of Isuparaglutide α in Australia on August 25, 2025 [1] - Approximately 200 participants are expected to be enrolled in the clinical trial [1]